Search results
Results from the WOW.Com Content Network
The main effect on cardiovascular morbidity is in patients with the metabolic syndrome, the features of which are attenuated by bezafibrate. [3] Studies show that in patients with impaired glucose tolerance, bezafibrate may delay progress to diabetes, [4] and in those with insulin resistance it slowed progress in the HOMA severity marker. [5]
PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They were originally indicated for dyslipidemia of cholesterol and more recently for disorders characterized by high triglycerides.
“The chance to achieve diabetes remission in patients receiving dapagliflozin plus calorie restriction is increased by 56%, as compared with those receiving calorie restriction alone,” he noted.
Gestational diabetes is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. [ 4 ] Type 2 diabetes mellitus and prediabetes are associated with changes in levels of metabolic markers, these markers could serve as potential prognostic or therapeutic targets for patients with prediabetes or Type 2 ...
Most fibrates can cause mild stomach upset and myopathy (muscle pain with CPK elevations). Fibrates decrease the synthesis of bile acid by down-regulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase expression, therefore making it easier for cholesterol to precipitate and increasing the risk for gallstones.
In 2011 Taylor showed that type 2 diabetes was a simple, reversible condition of excess fat within liver and pancreas. [5] This led to a series of studies, most recently the Diabetes Remission Clinical Trial which demonstrated that type 2 diabetes can be reversed to normal in Primary Care and that the underlying pathophysiological changes were ...
Each MetaboCard entry contains 130 data fields with 2/3 of the information being devoted to chemical/clinical data and the other 1/3 devoted to enzymatic or biochemical data. [31] The version 3.5 of the HMDB contains >16,000 endogenous metabolites, >1,500 drugs and >22,000 food constituents or food metabolites. [ 32 ]
This is a shortened version of the third chapter of the ICD-9: Endocrine, Nutritional and Metabolic Diseases, and Immunity Disorders.It covers ICD codes 240 to 279.The full chapter can be found on pages 145 to 165 of Volume 1, which contains all (sub)categories of the ICD-9.